EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Post Menopausal Osteoporosis - Pipeline Review, H1 2015

  • ID: 3259647
  • Report
  • April 2015
  • 86 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Radius Health, Inc.
  • MORE
Post Menopausal Osteoporosis - Pipeline Review, H1 2015

Summary

This, ‘Post Menopausal Osteoporosis - Pipeline Review, H1 2015’, provides an overview of the Post Menopausal Osteoporosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Post Menopausal Osteoporosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post Menopausal Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Radius Health, Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Post Menopausal Osteoporosis Overview
Therapeutics Development
Pipeline Products for Post Menopausal Osteoporosis - Overview
Pipeline Products for Post Menopausal Osteoporosis - Comparative Analysis
Post Menopausal Osteoporosis - Therapeutics under Development by Companies
Post Menopausal Osteoporosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Post Menopausal Osteoporosis - Products under Development by Companies
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Amgen Inc.
Chronos Therapeutics Limited
Eli Lilly and Company
Hanmi Pharmaceuticals, Co. Ltd.
Merck & Co., Inc.
Oncobiologics, Inc.
Paras Biopharmaceuticals Finland Oy
Pfizer Inc.
Radius Health, Inc.
Unigene Laboratories, Inc.
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aceclofenac + eperisone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abaloparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bazedoxifene acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
blosozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
calcitonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Postmenopausal Osteoporosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
odanacatib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romosozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
teriparatide biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post Menopausal Osteoporosis - Recent Pipeline Updates
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Jan 29, 2015: Radius Health Announces Oral Presentation of the ACTIVE Phase 3 Clinical Trial of Abaloparatide-SC for Postmenopausal Women With Osteoporosis at ICE/ENDO 2015
Dec 21, 2014: Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis
Nov 24, 2014: The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study of the Investigational Drug Abaloparatide in Postmenopausal Women With Osteoporosis
Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis
Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
Sep 15, 2014: New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density
Aug 13, 2014: Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director
Jan 09, 2014: Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems
Jan 02, 2014: Romosozumab phase 2 data published in New England Journal of Medicine show significant increases in bone mineral density at both spine and hip
Dec 31, 2013: Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Chronos Therapeutics Limited, H1 2015
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H1 2015
Post Menopausal Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015
Post Menopausal Osteoporosis - Pipeline by Pfizer Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Unigene Laboratories, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2015
Post Menopausal Osteoporosis - Dormant Projects, H1 2015
Post Menopausal Osteoporosis - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Amgen Inc.
Chronos Therapeutics Limited
Eli Lilly and Company
Hanmi Pharmaceuticals, Co. Ltd.
Merck & Co., Inc.
Oncobiologics, Inc.
Paras Biopharmaceuticals Finland Oy
Pfizer Inc.
Radius Health, Inc.
Unigene Laboratories, Inc.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll